Cytokeratin deposits in lymph nodes show distinct clinical significance from lymph node micrometastasis in human esophageal cancers

被引:33
作者
Doki, Y [1 ]
Ishikawa, O
Mano, M
Hiratsuka, M
Sasaki, Y
Kameyama, M
Ohigashi, H
Murata, K
Yamada, T
Miyashiro, I
Yokoyama, S
Ishiguro, S
Imaoka, S
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka 5378511, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Pathol, Osaka 5378511, Japan
关键词
esophageal cancer; micrometastasis; lymph node; cytokeratin; immunohistochemistry; neo-adjuvant chemotherapy; prognostic factor;
D O I
10.1006/jsre.2002.6506
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Cytokeratin immunostaining is the most common method used to identify micrometastatic cancer cells from the lymph nodes. However, contamination with hyalinized cytokeratin particles, frequently observed in the lymph nodes of esophageal cancer patients, can lead to misinterpretation of cytokeratin immunostaining. Materials and methods. Cytokeratin immunostaining (AE1/AE3) of surgically removed lymph nodes was performed for 41 cases of node-negative, but locally advanced (T3, T4), esophageal cancer patients. Cytokeratin immunoreactivity (CK) was classified as micrometastasis (MM) or cytokeratin deposit (CD) by the presence or absence of tumor nuclei in serial sections given hematoxylin-eosin staining. Results. CK (+) was observed in 18 patients (44%), including 11 with AM (+) (27%) and 10 with CD (+) (24%). There was no correlation between MM and CD, and neither was associated with clinicopathological factors, except for a high incidence of preoperative chemotherapy in CD (+) patients. The presence of CK did not affect postoperative survival of esophageal cancer patients at this limited stage, showing a 5-year survival rate of 57% for CK (+) and 64% for CK (-) (P = 0.6064). Interestingly, patients with AM (+) showed poorer prognosis than AM (5-year survival: 28% vs 79%, P = 0.0188), while CD patients tended to display better prognosis than CD (-) ones (5-year survival: 78% vs 56%, P = 0.1860). Conclusions. Evaluation by cytokeratin immunostaining of lymph nodes requires careful discrimination of CD from MM, in order to allow AIM to be used as a prognostic factor for esophageal cancer patients. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:75 / 81
页数:7
相关论文
共 27 条
[1]
RADICAL LYMPH-NODE DISSECTION FOR CANCER OF THE THORACIC ESOPHAGUS [J].
AKIYAMA, H ;
TSURUMARU, M ;
UDAGAWA, H ;
KAJIYAMA, Y .
ANNALS OF SURGERY, 1994, 220 (03) :364-373
[2]
Bone marrow-disseminated tumor cells in patients with carcinoma of the esophagus or cardia [J].
Bonavina, L ;
Soligo, D ;
Quirici, N ;
Bossolasco, P ;
Cesana, B ;
Deliliers, GL ;
Peracchia, A .
SURGERY, 2001, 129 (01) :15-22
[3]
MESOTHELIAL CELL INCLUSIONS IN MEDIASTINAL LYMPH-NODES MIMICKING METASTATIC CARCINOMA [J].
BROOKS, JSJ ;
LIVOLSI, VA ;
PIETRA, GG .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 93 (06) :741-748
[4]
Progressive changes in adherens junction structure during intestinal adenoma formation in Apc mutant mice [J].
Carothers, AM ;
Melstrom, KA ;
Mueller, JD ;
Weyant, MJ ;
Bertagnolli, MM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) :39094-39102
[5]
DOMAGALA W, 1992, ACTA CYTOL, V36, P241
[6]
Combined modality therapy for esophageal cancer. [J].
Gamliel Z. ;
Krasna M.J. .
Current Oncology Reports, 1999, 1 (2) :149-154
[7]
Glickman JN, 1999, CANCER, V85, P769, DOI 10.1002/(SICI)1097-0142(19990215)85:4<769::AID-CNCR3>3.0.CO
[8]
2-I
[9]
GOULD VE, 1995, VIRCHOWS ARCH, V425, P617
[10]
Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance [J].
Hosch, SB ;
Stoecklein, NH ;
Pichlmeier, U ;
Rehders, A ;
Scheunemann, P ;
Niendorf, P ;
Knoefel, WT ;
Izbicki, JR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) :1970-1975